Stifel raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$19 from C$17 and keeps a Buy rating on the shares.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter